Hormone replacement therapy in the aged: A state of the art review

Drugs and Aging

Volumn 8, Issue 3, 1996, Pages 193-213

  Jacobs, Sue ^a   Hillard, Timothy C ^a  

^a POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ATROPHY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; DEPRESSION; DRUG MECHANISM; DYSPEPSIA; ENDOMETRIUM CANCER; FEMALE; HEADACHE; HEART PROTECTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MASTALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYPHYLAXIS; TRANSDERMAL DRUG ADMINISTRATION; VAGINA ATROPHY;

EID: 0029874889     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608030-00005     Document Type: Review

References (202)

1. Coope J, Thompson JM. Poller L. Effects of 'natural oestrogen' replacement therapy on menopausal symptoms and blood clotting. BMJ 1975; 4: 139-43
2. Campbell S, Whitehead MI. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977; 4(1): 31-47
3. Siemmens JP, Wagner E. Oestrogen deprivation and vaginal function in postmenopausal women. JAMA 1982; 248: 445-8
4. Dennerstein L, Burrows GD, Hyman GJ, et al. Hormone therapy and affect. Maturitas 1979; 1: 247-59
5. Ditkoff EC, Crary WG, Cristo M, et al. Estrogen improved psychological function in asymptomatic postmenopausal women. Obstet Gynaecol 1991; 78: 991-5
6. Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BMJ 1973; 3: 515-8
7. Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980; ii: 1151-4
8. Christiansen C, Christiensen MS, McNair P, et al. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273-9
9. Stevenson JC, Cust MP, Ganger KF, et al. Effects of transdermal versus oral replacement therapy on bone density in the spine and proximal femur in post menopausal women. Lancet 1990; 335: 265-9
10. Hunt K, Vessey M, McPherson K. Mortality in cohort of long term users of hormone replacement therapy: an updating analysis. Br J Obstet Gynaecol 1990; 97: 1080-6
11. Ross RK, Paganini-Hill A, Mack TM, et al. Menopausal oestrogen therapy and protection from death and ischaemic heart disease. Lancet 1981; i: 858-61
12. Henderson BE, Paginini-Hill A, Ross RK. Oestrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159: 312-7
13. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal oestrogen therapy and cardiovascular disease. N Engl J Med 1991; 325: 756-62
14. Woolfe PH, Madans JH, Finucane FF, et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a natural cohort. Am J Obstet Gynecol 1991; 164: 489-91
15. Christiansen C, Christensen MS, Transbol IB. Bone mass in postmenopausal women after withdrawal of oestrogen therapy. Lancet 1981; i: 459-61
16. Ettinger B, Grady D. The waning effects of postmenopausal oestrogen therapy on osteoporosis. N Engl J Med 1993; 329: 1192-3
17. Felson DT, Zhang YY, Hannan MT, et al. The effect of postmenopausal oestrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-6
18. Brinton JA, Hoover R, Fraumeni Jr JF. Menopausal oestrogens and breast cancer risk: an expanded case controlled study. Br J Cancer 1986; 54: 825-32
19. Dupont WD, Page DL. Menopausal oestrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72
20. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effects of oestrogen replacement therapy and the risk of breast cancer. JAMA 1991; 265: 1985-90
21. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062-71
22. Sturdee DW, Brincat M. The hot flush in the menopause. In: Studd JWW, Whitehead MI, editors. The menopause. Oxford: Blackwell Scientific Publications, 1988: 24-42
23. Padwick ML, Endacott J, Whitehead MI. Efficacy, acceptability and metabolic effects of transdermal oestradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-91
24. Patterson ME. A randomised double blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982; 84: 464-72
25. Kicovic PM, Cartes-Prieto J, Luisi M, et al. Placebo controlled cross-over study of the effects of Org OD14 in menopausal women. Reproduction 1982; 6: 81-91
26. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double blind trial of non-hormonal medication. BMJ 1974; 1: 409-12
27. Lindsay R, Hart DM. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978; 1: 21-5
28. Hunter MS. Psychological aspects of the climacteric and postmenopause. In: Studd JWW, Whitehead MI, editors. The menopause. Oxford: Blackwell Scientific Publications, 1988: 55-64
29. Magos AC, Brewster E, Singh R, et al. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the pre-menstrual syndrome. Br J Obstet Gynaecol 1986; 93: 1290-6
30. Sherwin BB, Gilford MM. A prospective one year study of oestrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989; 73: 759-66
31. Leiblum S, Bachman G, Kenmaan E, et al. Vaginal atrophy in the postmenopausal woman: the importance of sexual activity and hormones. JAMA 1983; 249: 2195-8
32. Smith P. Age changes in the female urethra. Br J Urol 1972; 44: 667-76
33. Raz R, Stamm WE. A controlled trial of intravaginal oestriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753-6
34. Nathorst-Boos J, Wickland I, Mattsson LA, et al. Is sexual life influenced by transdermal oestrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynaecol Scand 1993; 72: 656-60
35. Wilson PD, Faragher B, Butler B, et al. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 1987; 44: 568-74
36. Melton III LJ. Etiology, diagnosis and management. In: Riggs BL, Melton IJ, editors. Epidemiology of fractures. New York: Raven Press, 1988: 133-54
37. Jensen J, Christiansen C, Boesen J, et al. Epidemiology of postmenopausal spinal and longbone fractures: a unifying approach to postmenopausal osteoporosis. Clin Orthop 1982; 166: 75-81
38. Farmer ME, White LR, Brody JA, et al. Race and sex differences in hip fracture incidence. Am J Public Health 1984; 74: 1374-80
39. Miller CW. Survival and ambulation following hip fractures. Bone Joint Surg 1978; 60A: 930-4
40. Grimley Evans J, Prudham D, Wandless I. A prospective study of fractured proximal femur: incidence and outcome. Public Health 1979; 93: 235-41
41. Melton LJ, Riggs BL. Epidemiology of age related fractures. In: Avioli LL, editor. The osteoporotic syndrome. New York: Grune and Stratton, 1983; 45-72
42. Purdie DW. Broken bones - a gynaecological problem. Br J Obstet Gynaecol 1988; 95: 737-9
43. Stevenson JC. Osteoporosis: pathogenesis and risk factors. Ballieres Clin Endocrinol Metab 1988; 2: 97-101
44. Dempster DEW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797-801
45. Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodelling. J Lab Clin Med 1978; 92: 964-70
46. Genant HK, Cann CE, Ettinger B, et al. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Arch Intern Med 1982; 97: 699-705
47. Riis, Thomsen K, Strom V, et al. The effect of percutaneous oestradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynaecol 1987; 156: 61-5
48. Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994; 4: 341-8
49. Al-Azzawi, Hart DM, Lindsay R. Long term effects of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. BMJ 1987; 294: 1261-2
50. Stevenson JC, Kanis JA, Christiansen C. Bone density measurement [letter]. Lancet 1992; 339: 370-1
51. Gordan GS, Picchi J, Roof BS. Anti-fracture efficacy of long term oestrogens for osteoporosis. Trans Assoc Am Physicians 1973; 86: 326-32
52. Hutchinson TA, Polanski SN, Feinsten AR. Postmenopausal oestrogens protect against fractures of hip and distal radius: a case controlled study. Lancet 1979; ii: 705-9
53. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of oestrogen. N Engl J Med 1980; 303: 1195-8
54. Ettinger B, Genant HK, Cann CE. Long term oestrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 318-24
55. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of oestrogens in postmenopausal women. N Engl J Med 1987; 317: 1169-74
56. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124-8
57. Purdie DW, Horsman A. Population screening and the prevention of osteoporosis. In: Drife JO, Studd JWW, editors. HRT and osteoporosis. London: Springer-Verlag, 1990: 251-64
58. Quigley MET, Martin PL, Burnier AM, et al. Oestrogen therapy and bone loss in elderly women. Am J Obslet Gynecol 1987; 156: 1516-23
59. Lindsay R, Tohme JF. Oestrogen treatment of patients with established post menopausal osteoporosis. Obstet Gynaecol 1990; 76: 290-5
60. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestogen therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol 1994; 40: 671-7
61. Horowitz M, Wishart JM, Need AT, et al. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin Endocrinol 1993; 39: 649-55
62. Stevenson JC, Lees B, Davenport M, et al. Determinants of bone density in normal women: risk factors for future osteoporosis. BMJ 1989; 298: 924-8
63. Purdie DW. Screening for osteoporosis. 27th British Congress of Obstetrics and Gynaecology [abstract no. 431]. 1995 Jul 4-7; Dublin. Lancashire: Parthenon Publishing, 1995
64. Riggs BL, Baylick DJ, Kleerekoper M, et al. Incidence of hip fractures in osteoporotic women treated with sodium fluoride. Bone Min Res 1987; 2: 123-6
65. Chesnut CH, Ivey JL, Gruber HE, et al. Stanozolol in postmenopausal osteoporosis: therapeutic efficiency and possible mechanisms for action. Metabolism 1983; 32: 571-80
66. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42
67. Reeve J, Davies UM, Arlot M, et al. Parathyroid peptide (hPTH 1-34) in the treatment of osteoporosis. In: Kleerekoper M, Krane SM, editors. Clinical disorders of bone and mineral metabolism. New York: Liebert, 1989: 621-8
68. Overgaard K, Riis B, Christiansen C, et al. Nasal calcitonin in the treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-42
69. Reginster JY, Denis D, Albert A, et al. One year controlled randomised trial of prevention of early postmenopausal bone loss by tiludronate. Lancet 1989; ii: 1469-71
70. Lindsay R, Hart DM, Kraszewski A. Prospective double blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. BMJ 1980; 280: 1207-9
71. New treatments for osteoporosis [editorial]. Lancet 1990; 335: 1065-6
72. Bush TL. The epidemiology of cardiovascular disease in older persons. Aging 1991; 3: 3-8
73. Stampfer MJ, Coldtitz LA. Oestrogen therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63
74. Falkeborne M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-8
75. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994; 62 Suppl. 2: 176S-9S
76. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989; 43: 173-8
77. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988; 297: 519-22
78. Posthuma WF, Westendrop RG, Vandenbroucke JP. Cardio-protective effects of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268-9
79. Vandenbroucke JP. Postmenopausal oestrogen and cardio-protection. Lancet 1991; 337: 833-4
80. Petitti DB. Coronary heart disease and oestrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 1994; 4: 115-8
81. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell Jr DR, editor Menopause: physiology and pharmacology. Chicago: Yearbook Medical Publishers, 1987: 187-208
82. Lobo RA. Clinical review 27: effects of hormone replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925-30
83. Barrett-Conner E, Bush TL. Oestrogen and coronary heart disease in women. JAMA 1991; 265: 1861-7
84. Williams JK, Adams MR, Herrington DM, et al. Short term administration of oestrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992; 20: 452-9
85. McGill HC. Sex steroid hormone receptors in the cardiovascular system. Post Grad Med 1989 Apr: 64-8
86. Bourne TH, Hillard TC, Whitehead MI, et al. Oestrogens, arterial status and postmenopausal women. Lancet 1990; i: 1470-1
87. Ganger KF, Vyas SJ, Whitehead, et al. Pulsatility index in the internal carotid artery is influenced by transdermal oestradiol and time since menopause. Lancet 1991; 338: 839-42
88. Pines A, Fisman EZ, Levo Y, et al. Effect of hormone replacement therapy in normal postmenopausal women: measurements of doppler-derived parameters of aortic flow. Am J Obstet Gynecol 1991; 164: 806-12
89. Collins P, Rosano GMC, Jiang C, et al. Cardiovascular protection by oestrogen - a calcium antagonistic effect. Lancet 1993; 341: 1264-5
90. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992; 106: 739-45
91. Mugge A, Riedel M, Barton M, et al. Endothelium independent relaxation of human coronary arteries by 17-beta oestradiol in vitro. Cardiovasc Res 1993; 27: 1939-42
92. Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas 1983; 5: 134-42
93. Ley CJ, Lees B, Stevenson JC. Sex and menopause-associated changes in body fat distribution. Am J Clin Nutr 1992; 55: 950-4
94. Walton C, Godsland IF, Proudler AJ. The effects of age and the menopause on insulin sensitivity, secretion and elimination in non-obese healthy women. Eur J Clin Invest 1993;23:466-73
95. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846-53
96. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 1992; 6 Suppl. 3: 5-10
97. Crook D, Godsland IF, Wynn V. Ovarian hormone plasma lipoproteins. In: Studd JWW, Whitehead MI, editors. The menopause. Oxford: Blackwell Scientific Publications, 1988: 168-80
98. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90
99. Lobo RA, Notelovitz M, Bernsyein L, et al. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise and oestrogen. Am J Obstet Gynecol 1992; 166: 1182-90
100. Nabulusie AA, Folsom AR, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Eng J Med 1993; 328: 1069-75
101. La Rosa JC. Metabolic effects of oestrogens and progestins. Fertil Steril 1994; 62 Suppl. 2: 140-6
102. Walsh BW, Schiff I, Rosna B, et al. Effects of postmenopausal oestrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-204
103. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral oestrogen/progestogen replacement therapy: efffects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-5
104. Ottosson UB, Johansson BG, Von Schoultz B. Subfractions of high density lipoprotein cholesterol during oestrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 152: 1085-91
105. Haarbo J, Hassanger C, Jensen, et al. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal oestrogen replacement therapy combined with either 19-nortestoslerone derivatives or 17-hydroproxyprogesterone derivatives. Am J Med 1991; 90: 584-9
106. Miller VT, Muersing RA, La Rosa JC, et al. Effects of conjugated equine oestrogen with and without three different progestogens on lipoproteins, high density lipoprotein subfractions, and apolipoprotein A1. Obstet Gynecol 1991; 77: 235-40
107. Lobo RA, Picker JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated oestrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 897-5
108. Kim CJ, Jang MC, Cho DM, et al. Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thrombosis 1994; 14: 275-81
109. Farish E, Rolton MA, Barnes JF. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 1991; 303: 694
110. Soma M, Fumagalli R, Rolettie R, et al. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women. Lancet 1991; 337: 612
111. Hillard TC, Bourne TH, Whitehead MI, et al. Differential effects of transdermal oestradiol and sequential progestogens on impedance to flow with the uterine arteries of postmenopausal women. Fertil Steril 1992; 58: 959-63
112. Yancey MK, Hannan CJ, Plymate SR, et al. Serum lipids and lipoproteins in continuous and cyclical medroxyprogesterone acetate treatment in postmenopausal women treated with conjugate oestrogens. Fertil Steril 1990; 54: 778-82
113. Vaziri SM, Evans JC, Larson MG. The impact of female hormone usage on the lipid profile: the Framingham offspring study. Arch Intern Med 1993; 153: 2200-6
114. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of oestrogen replacement therapy. Arch Intern Med 1991; 151: 75-8
115. Sullivan JM, Vander-Zwaag R, Lemp GF, et al. Postmenopausal oestrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358-63
116. Mashchak CA, Lobo RA, Dozono-Takano RA, et al. Comparison of pharmacodynamic properties of various oestrogen formulations. Am J Obstet Gynecol 1982; 144: 511-8
117. Chetowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal oestradiol. N Engl J Med 1986; 314: 1615-20
118. Powers MS, Schenkel L, Darley PE, et al. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17-beta oestradiol: comparison with conventional oral oestrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-106
119. Fraser DI, Parsons A, Whitehead MI, et al. The optimal dose of oral norethinderone acetate for addition to transdermal oestradiol: a multi-centre study. Fertil Steril 1990; 53: 460-8
120. Transdermal HRT Investigators Group. A randomised study to compare the effectiveness, tolerability and acceptability of two different transdermal oestradiol replacement therapies. Int J Fertil 1993; 38: 5-11
121. Hart DM, Al-Azzawi F, Farish E. Effects of ossopan alone, oestradiol implants alone or both therapies combined on bone density and bone biochemistry in oophorectomized women. In: Christiansen C, Johansen J, Riis B, editors. Osteoporosis 1987. Copenhagen: Osteopress, 1987: 572-4
122. Savvas M, Studd JWW, Norman S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in postmenopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992; 99: 757-60
123. Ganger KF, Fraser D, Whitehead MI, et al. Prolonged endometrial stimulation associated with oestradiol implants. BMJ 1989; 300: 436-8
124. Studd JWW, Savvas M, Watson N, et al. The relationship between plasma oestradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol 1990; 163: 1474-9
125. Studd JWW, Holland EFN, Leather AT. The dose responses of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994; 101: 787-91
126. Ganger KF, Cust MP, Whitehead MI. Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. BMJ 1989; 299: 601-2
127. Garnett T, Studd JWW, Henderson A. et al. Hormone implants and tachyphylaxis. Br J Obstet Gynaecol 1990; 97: 917-21
128. Iosif CS. Effects of protracted administration of estriol on the lower genito-urinary tract in postmenopausal women. Arch Gynaecol Obstet 1992; 251: 115-20
129. Erikson PS, Rasmussen H. Low dose 17-beta oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992; 44: 137-44
130. Smith P, Heimer G, Lindskog M, et al. Oestradiol releasing vaginal ring for treatment of postmenopausal uro-genital atrophy. Maturitas 1993; 16: 145-54
131. Lindsay R, Hart DH, Clark AS. The minimum effective dose of oestrogen for the prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-62
132. Christiansen C, Christianson MS, Larson NE, et al. Pathophysiological mechanisms of oestrogen effect on bone metabolism: dose response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982; 55: 1124-30
133. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low dose oestrogen and calcium. Ann Intern Med 1987; 106: 40-5
134. Holland EF, Leather AT, Studd JW. The effect of 25mg percutaneous oestradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994; 83: 43-6
135. Naessen T, Persson I, Thor L. Maintained bone density at advanced years long term treatment with low dose oestradiol implants. Br J Obstet Gynaecol 1993; 100: 454-9
136. Maclennan AH, Maclennan A, O'Neill S, et al. Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy. Med J Aust 1992; 157: 167-70
137. Sturdee DW, Wade-Evans T, Patterson MEL, et al. Relations between bleeding pattern, endometrial histology and oestrogen treatment in postmenopausal women. BMJ 1978; 1: 1575-7
138. Whitehead MI, King RJB, McQueen J, et al. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestin therapy. J R Soc Med 1979; 72: 322-7
139. Arafat ES, Hargrove JT, Maxson WS, et al. Sedative and hypnotic effects of oral administration of micronised progesterone may be related through its metabolism. Am J Obstet Gynecol 1988; 159: 1203-9
140. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171-97
141. Siddle NC, Jessinger DK, Whitehead MI, et al. Effects on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 1990; 97: 1093-100
142. Van der Mooren MJ, Demacker PN, Thomas CMG. Beneficial effects on serum lipoproteins by 17 beta-oestradioldydrogesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynaecol Reprod Biol 1992; 47: 153-60
143. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375-81
144. Andersson K, Mattsson LA, Rybo G, et al. Intra-uterine release of levonorgestrol - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-7
145. Whitehead MI, Fraser D, Schenkel L, et al. Transdermal administration of cyclical oestrogen/progestogen hormone replacement therapy. Lancet 1990; 335: 310-2
146. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75 Suppl.: 59-76
147. Hirvenon E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking oestrogen? Maturitas 1995; 21: 39-44
148. Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700
149. Wren BG, Brown L. Compliance with hormone replacement therapy. Maturitas 1990; 13: 17-21
150. Archer DF, Pickar JM, Bottinglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated oestrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686-92
151. Padwick ML, Pryse-Davies J, Whitehead MI. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving oestrogens. N Engl J Med 1986; 315: 930-4
152. Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogens/progestogen replacement therapy? Lancet 1994; 344: 979-82
153. Ziel JK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated oestrogens. N Engl J Med 1975; 293: 1167-70
154. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous oestrogen and endometrial carcinoma. N Engl J Med 1475; 293: 1164-7
155. Cramer DW, Knapp RC. Review of epidemiologic studies of endometrial cancer and oestrogen. Obstet Gynecol 1979; 54: 321-6
156. Whitehead MI, Townsend PT, Pryse-Davies J. Effects of oestrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl Med 1981; 305: 1599-605
157. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens. Results of a prospective study. BMJ 1989; 298: 147-51
158. Voigt LF, Weiss NS, Chu J, et al. Progestogen supplements of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-7
159. Creasmen WT, Henderson D, Hinshaw W, et al. Oestrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67: 326-30
160. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case controlled study of menopausal oestrogen therapy and breast cancer. JAMA 1980; 243: 1635-9
161. Hoover R, Glass A, Finkle WD, et al. Conjugated oestrogens and breast cancer risk in women. J Clin Invest 1981; 67: 815-20
162. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-8
163. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after oestrogen and oestrogen/progestogen replacement. N Engl J Med 1989; 321: 293-7
164. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93
165. Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. BMJ 1992; 305: 1403-8
166. Kelsey JL, Fisher DB, Holford TR, et al. Exogenous oestrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67: 327-3
167. Hyatt RA, Bawol R, Friedman GD, et al. Exogenous oestrogen and breast cancer after bilateral oophorectomy. Cancer 1984; 54: 139-44
168. Kaufman, DW, Miller DR, Rosenberg L, et al. Non-contraceptive oestrogen use and the risk of breast cancer. JAMA 1984; 252: 63-7
169. Wingo PA, Layde PM, Lee NE, et al. The risk of breast cancer in postmenopausal women who have used oestrogen replacement therapy. JAMA 1987; 257: 209-15
170. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-42
171. Jick H, Walker AM, Watkins RN, et al. Replacement oestrogens and breast cancer Am J Epidemiol 1980; 112: 586-93
172. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
173. Hulka BS, Chambless LE, Deubner DC, et al. Breast cancer and oestrogen replacement therapy Am J Obstet Gynecol 1982; 143-644
174. Gambrell Jr RD, Maier R, Sanders B. Decreased incidence of breast cancer in postmenopausal oestrogen and progestogen? Obstet Gynecol 1983; 62: 435-43
175. Whitehead MI, Loho RA. Progestogen use in postmenopausal women. Consensus conference. Lancet 1988; ii: 1243-4
176. Gapstur SM, Potter JM, Sellers TA, et al. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992; 136: 1221-31
177. Hunt K, Vessey M, McPherson K, et al. Long term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-35
178. Bergvist L, Adami HO, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen/progestogen replacement therapy. Am J Epidemiol 1989; 130: 221-8
179. Love RR, Maxess RB, Tormey DC, et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988; 12: 297-302
180. Fernander T, Cedermark B, Mattsson A. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-30
181. Creasman WT. Oestrogen replacement therapy: is previously treated cancer a contra-indication? Obstet Gynecol 1991; 77: 308-12
182. Wild AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372-5
183. Marchant DJ. Supplemental oestrogen replacement. Cancer 1994; 74: Suppl. 1: 512-7
184. Weiss NS, Lyon JL, Krishnmurthy S, et al. Non-contraceptive oestrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982; 68: 95-8
185. Cust MP, Gangar KF, Whitehead MI. Oestrogens and cancer. In: Drife JO, Studd JWW, editors. HRT and osteoporosis. London: Springer-Verlag, 1990; 177-87
186. Gruchow W, Anderson AJ, Barboriak JJ, et al. Post menopausal use for oestrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954-63
187. Boston Collaborative Drugs Surveillance Programme. Surgically confirmed gall bladder disease, venous thromboembolism and breast tumours in relation to postmenopausal oestrogen use. N Engl J Med 1974; 290: 15-9
188. Van Erpecum KJ, Van Berg Henegouwen GP, Verschoor L, et al. Different hepatobillary effects of oral and transdermal oestradiol in postmenopausal women. Gastroenterology 1991; 101: 594-5
189. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306-16
190. Hillard TC, Siddle NC, Fraser D, et al. Continuous combined conjugated equine oestrogen/progestogen therapy: effects of medroxyprogesterone acetate and norethinderone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167: 1-7
191. Leather AT, Savvas M, Studd JWW. Endometrial histology and bleeding patterns after eight years of continuous combined oestrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1008-10
192. Rymer J, Fogelman I, Champman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994; 101: 53-6
193. Trevoux R, Dievlangard P, Blum A. Efficacy and safety of ORG OD14 in the treatment of climacteric complaints. Maturitas 1983; 5: 89-96
194. Crona N, Silfverstolpe G, Samsioe G. A double blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol 1983; 102: 451-5
195. Kloosterboer HJ, Bendek-Jaszamnn LJ, Kicovic PM. Long term effects of ORG OD14 on lipid metabolism in postmenopausal women. Maturitas 1990; 12: 37-42
196. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol (Copenh) 1993; 128; 259-62
197. National Opinion Poll. The menopause revolution. London: Ciba Geigy, 1992
198. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332-4
199. Draper J, Roland M. Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis. BMJ 1990; 300: 786-8
200. Wallace WA, Price VH, Elliot CA, et al. Hormone replacement therapy acceptability to Nottingham postmenopausal women with a risk factor for osteoporosis. J R Soc Med 1990; 83: 699-701
201. Hahn RG. Compliance considerations with oestrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989; 161: 1854-8
202. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy in menopause. Obstet Gynecol 1990; 75 Suppl. 4: 77S-83S